Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database-Reference-Cited by-同舟云学术

Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database

Published:2019-12-11 Issue:3 Volume:29 Page:279-287
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Huber Carola A.¹^ORCID,Agosti Reto²,Näpflin Markus¹,Blozik Eva¹³

Affiliation:

1. Department of Health SciencesHelsana Insurance Group Zürich Switzerland

2. Headache Center HirslandenHirslanden Hospital Group Zollikon Switzerland

3. Department of MedicineUniversity Medical Centre Freiburg Freiburg Germany

Funder

Novartis Pharma AG, Basel, Switzerland

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.4938

Reference45 articles.

1. Funding of Headache Research in Europe

2. An epidemiological case-control study of migraine and its associated comorbid conditions

3. The Medical Costs of Migraine and Comorbid Anxiety and Depression

4. Costs of Acute Headache Medication Use and Productivity Losses Among Patients with Migraine: Insights from Three Randomized Controlled Trials

5. The cost of headache disorders in Europe: the Eurolight project

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of COVID-19 on Mental Healthcare Utilization in Switzerland Was Strongest Among Young Females—Retrospective Study in 2018–2020;International Journal of Public Health;2023-05-19